Literature DB >> 3365658

Histopathologic grading in spindle cell soft tissue sarcomas.

J M Coindre1, B B Nguyen, F Bonichon, I de Mascarel, M Trojani.   

Abstract

Tumor grade is currently the most important factor in the staging of patients with soft tissue sarcomas. In previous studies, a histopathologic grading system was described and its reproducibility was tested. The current study reports the value of this grading system in spindle cell sarcomas, which represent about one half of all adult soft tissue sarcomas, the precise identification of which is often difficult. One hundred twenty-five such tumors were studied retrospectively. Malignant fibrous histiocytoma was the most frequent histologic type, followed by leiomyosarcoma, neurosarcoma, and fibrosarcoma. Tumor grade was correlated with the advent of metastases and survival, and was the main prognostic factor according to multifactorial analysis introducing clinical prognostic factors.

Entities:  

Mesh:

Year:  1988        PMID: 3365658     DOI: 10.1002/1097-0142(19880601)61:11<2305::aid-cncr2820611126>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  18 in total

1.  Transformed dermatofibrosarcoma protuberans: a clinicopathological study of eight cases.

Authors:  Z Szollosi; Z Nemes
Journal:  J Clin Pathol       Date:  2005-07       Impact factor: 3.411

Review 2.  [Multimodality therapy concepts for soft tissue sarcomas].

Authors:  C-M Wendtner; S Delank; H Eich
Journal:  Internist (Berl)       Date:  2010-11       Impact factor: 0.743

3.  Risk assessment based on FDG-PET imaging in patients with synovial sarcoma.

Authors:  Jennifer W Lisle; Janet F Eary; Janet O'Sullivan; Ernest U Conrad
Journal:  Clin Orthop Relat Res       Date:  2008-12-02       Impact factor: 4.176

4.  Stromal tumours of the gastrointestinal tract: a clinicopathological and ploidy analysis of 33 cases.

Authors:  E Lerma; E Oliva; D Tugués; J Prat
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

5.  Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO).

Authors:  Loïc Chaigneau; Anna Patrikidou; Isabelle Ray-Coquard; Thibaud Valentin; Claude Linassier; Jacques Olivier Bay; Laurence Moureau Zabotto; Emmanuelle Bompas; Sophie Piperno-Neumann; Nicolas Penel; Thierry Alcindor; Maryline Laigre; Cecile Guillemet; Sebastien Salas; Anne Hugli; Julien Domont; Marie Pierre Sunyach; Axel Lecesne; Jean Yves Blay; Virginie Nerich; Nicolas Isambert
Journal:  Oncologist       Date:  2018-06-22

6.  Neoadjuvant treatment of soft tissue sarcoma.

Authors:  Daniela Greto; Lorenzo Livi; Calogero Saieva; Pierluigi Bonomo; Icro Meattini; Mauro Loi; Lucia Di Brina; Giovanni Beltrami; Domenico Campanacci; Guido Scoccianti; Rodolfo Capanna; Monica Mangoni; Fabiola Paiar; Alessandro Franchi; Giampaolo Biti
Journal:  Radiol Med       Date:  2013-11-26       Impact factor: 3.469

7.  Prognostic factors and metastatic patterns in primary myxoid/round-cell liposarcoma.

Authors:  J Haniball; V P Sumathi; L-G Kindblom; A Abudu; S R Carter; R M Tillman; L Jeys; D Spooner; D Peake; R J Grimer
Journal:  Sarcoma       Date:  2011-11-28

8.  Local tumour response to neoadjuvant therapy with 2-aminoethyl dihydrogen phosphate in dogs with soft tissue sarcoma.

Authors:  Patrícia Ferreira de Castro; Durvanei Augusto Maria; Ana Carolina Brandão de Campos Fonseca Pinto; Geni Cristina Fonseca Patricio; Julia Maria Matera
Journal:  Vet Med Sci       Date:  2022-02-22

9.  A giant subcutaneous leiomyosarcoma arising in the inguinal region.

Authors:  Kazuhito Yajima; Yoshio Shirai; Nobuhiro Fujita; Daisuke Sato; Hajime Umezu; Katsuyoshi Hatakeyama
Journal:  World J Surg Oncol       Date:  2005-02-24       Impact factor: 2.754

10.  Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors.

Authors:  Eirini Thanopoulou; Khin Thway; Komel Khabra; Ian Judson
Journal:  Clin Sarcoma Res       Date:  2014-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.